Candriam Luxembourg S.C.A. reduced its position in Omeros Corporation (NASDAQ:OMER) by 24.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 81,370 shares of the biopharmaceutical company’s stock after selling 27,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Omeros Corporation were worth $1,620,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Nwam LLC increased its stake in Omeros Corporation by 0.5% in the first quarter. Nwam LLC now owns 44,790 shares of the biopharmaceutical company’s stock worth $677,000 after buying an additional 232 shares during the last quarter. Wells Fargo & Company MN increased its stake in Omeros Corporation by 5.5% in the first quarter. Wells Fargo & Company MN now owns 37,717 shares of the biopharmaceutical company’s stock worth $571,000 after buying an additional 1,960 shares during the last quarter. American International Group Inc. increased its stake in Omeros Corporation by 15.2% in the first quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,232 shares during the last quarter. Swiss National Bank increased its stake in Omeros Corporation by 5.7% in the first quarter. Swiss National Bank now owns 67,100 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 3,600 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in Omeros Corporation by 6.6% in the first quarter. Nationwide Fund Advisors now owns 70,680 shares of the biopharmaceutical company’s stock worth $1,069,000 after buying an additional 4,407 shares during the last quarter. Institutional investors own 45.11% of the company’s stock.

Omeros Corporation (NASDAQ:OMER) opened at 23.45 on Friday. Omeros Corporation has a 12-month low of $7.20 and a 12-month high of $27.09. The company’s market cap is $1.05 billion. The stock’s 50 day moving average is $21.51 and its 200-day moving average is $16.16.

Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.12. The business had revenue of $17.15 million for the quarter, compared to analyst estimates of $14.63 million. During the same quarter in the previous year, the company posted ($0.32) EPS. The business’s revenue for the quarter was up 71.5% compared to the same quarter last year. Analysts predict that Omeros Corporation will post ($1.26) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Omeros Corporation (NASDAQ:OMER) Shares Sold by Candriam Luxembourg S.C.A.” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/12/omeros-corporation-nasdaqomer-shares-sold-by-candriam-luxembourg-s-c-a.html.

A number of research firms have issued reports on OMER. BidaskClub downgraded shares of Omeros Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, June 28th. Maxim Group set a $23.00 target price on shares of Omeros Corporation and gave the stock a “buy” rating in a research report on Monday, May 22nd. Cantor Fitzgerald downgraded shares of Omeros Corporation from a “buy” rating to a “neutral” rating and cut their target price for the stock from $21.00 to $15.00 in a research report on Thursday, May 11th. Wedbush reiterated an “outperform” rating and issued a $47.00 target price on shares of Omeros Corporation in a research report on Wednesday, May 10th. Finally, ValuEngine upgraded shares of Omeros Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $32.80.

In related news, VP Michael A. Jacobsen sold 12,000 shares of the stock in a transaction on Friday, June 16th. The shares were sold at an average price of $24.95, for a total transaction of $299,400.00. Following the completion of the transaction, the vice president now owns 19,500 shares in the company, valued at $486,525. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael A. Jacobsen sold 24,000 shares of the stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the transaction, the vice president now owns 2,650 shares of the company’s stock, valued at approximately $56,180. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.